Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

103.09 +3.14 (+3.14%)
Streaming Delayed Price Updated: 3:18 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ligand Pharm

< Previous 1 2 3 Next >
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Second Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
5 Best Short-Term Stocks to Consider Investing In
Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. 
Via MarketBeat
Ligand to Acquire APEIRON Biologics AG for $100 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Participate in Upcoming Investor Conferences
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports First Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
From Palvella Therapeutics
Via GlobeNewswire
Ligand Reports Third Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand To Report Third Quarter 2023 Financial Results On November 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.